neuroinspire™ stereotactic neurosurgery planning standalone software cleared for sale in the USA
16 October 2017
Renishaw is pleased to announce that the Food and Drug Administration (FDA) has cleared the latest version of neuroinspire stereotactic neurosurgery planning standalone software for sale in the USA.
neuroinspire software fuses MRI and CT datasets into a 3D volume, enabling neurosurgeons to identify and outline regions of interest, and determine the best available approach to the target. Thorough planning in the pre-operative stage can minimise the chance of hitting key anatomy during the procedure, and improve patient outcomes.
The neuroinspire software can be used to plan a range of stereotactic procedures and assist neurosurgeons to target anatomy concealed deep within the brain tissue. Neurosurgeons using neuroinspire can create plans based on procedure type, with planning tools tailored to the task in hand. Users can choose to work on a Deep Brain Stimulation (DBS) to reduce the symptoms of Parkinson's disease, a Stereoelectroencephalography (SEEG) to identify the area of the brain responsible for epileptic seizures or a biopsy to assist with the diagnosis of a brain tumour.
On the FDA's decision, Head of Regulatory Affairs and Quality Assurance Roberto Liddi commented, “The success of the clearance application was the result of a great team effort across all areas of the Renishaw Neurological Products Division. We are delighted that neuroinspire standalone software is now available on the American market, and look forward to working with neurosurgeons in the USA to streamline complex neurosurgical procedures.”
The latest version of neuroinspire software supports more data formats than previous versions of the software, and features semi-automatic profiling which allows surgeons to quickly and intuitively delineate anatomical features.
Additional modules for neuroinspire software are available, including region of interest based automatic registration, PACS connectivity for retrieving patient data from the hospital network and the Cerefy Electronic Clinical Brain Atlas for cross-referencing target placement.
For further information on Renishaw's range of products for stereotactic neurosurgery, visit www.renishaw.com/neuro
News release:- neuroinspire™ stereotactic neurosurgery planning standalone software cleared for sale in the USA
Renishaw is pleased to announce that the Food and Drug Administration (FDA) has cleared the latest version of neuroinspire™ stereotactic neurosurgery planning standalone software for sale in the USA.
- neuroinspire V5 SEEG
For further images, videos, company biographies or information on Renishaw and its products, visit our Media Hub.